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Comprehensive analysis of common mitochondrial DNA variants
and colorectal cancer risk
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Research Institute, Cancer Research UK, London WC2A 3PX, UK
Several lines of evidence implicate mitochondrial dysfunction in the development of cancer. To test the hypothesis that common
mtDNA variation influences the risk of colorectal cancer (CRC), we genotyped 132 tagging mtDNA variants in a sample of 2854
CRC cases and 2822 controls. The variants examined capture B80% of mtDNA common variation (excluding the hypervariable
D-loop). We first tested for single marker associations; the strongest association detected was with A5657G (P¼ 0.06). Overall the
distribution of association P-values was consistent with a null distribution. Next, we classified individuals into the nine common
European haplogroups and compared their distribution in cases and controls. This analysis also provided no evidence of an
association between mitochondrial variation and CRC risk. In conclusion, our results provide little evidence that mitochondrial genetic
background plays a role in modifying an individual’s risk of developing CRC.
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Approximately 35% of colorectal cancer (CRC) can be ascribed to
inherited susceptibility (Lichtenstein et al, 2000). Mendelian
predisposition syndromes associated with mutations in known
genes (APC, DNA mismatch repair (MMR) genes, MYH, SMAD4,
ALK3 and STK11/LKB1); however, account for o6% of the overall
incidence of the disease (Aaltonen et al, 2007). The recent advent
of genome-wide association studies has lead to the discovery of
several common, low-penetrance susceptibility loci for CRC
(Broderick et al, 2007; Tomlinson et al, 2007, 2008; Tenesa et al,
2008), thereby providing incontrovertible evidence for common
genetic variation as a basis for CRC susceptibility.
There is increasing evidence that common variation in the
mitochondrial DNA (mtDNA) may be functionally relevant to the
development of a range of common diseases. Notably, mtDNA
polymorphisms have been implicated in a variety of late-onset
diseases, including type 2 diabetes (Lowell and Shulman, 2005),
Alzheimer’s, and Parkinson’s disease (Schapira, 1999).
Mitochondria play an essential role in energy metabolism, the
generation of reactive oxygen species (ROS) and the regulation of
apoptosis (Wallace, 2005), all of which have been implicated in the
development of a number of different cancers (Benhar et al, 2002).
Low levels of ROS regulate cellular signalling and are essential for
normal cell proliferation; ROS production is increased in tumour
cells causing oxidative stress and DNA damage, which can lead to
genetic instability (Burdon, 1995). Thus, ROS are thought to play
multiple roles in the initiation, progression, and maintenance
of tumours.
Somatic mtDNA mutations can be identified in a wide variety
of malignancies, including CRC (Chatterjee et al, 2006), although
it is unclear whether these are causal or a consequence of
the neoplastic process. Given the essential role of mitochondria
in ROS generation and regulation of apoptosis, it is however
plausible that variant mitochondrial function may directly
contribute to an individual’s risk of developing cancer. Such
an assertion is supported by a recent report implicating
polymorphic mtDNA variants in susceptibility to breast cancer
(Bai et al, 2007).
To date no comprehensive evaluation of the hypothesis that
common mtDNA variants influence the risk of developing CRC has
been conducted. To address this we have genotyped 132 tagging
mtDNA variants, which capture B80% of all of the common
mitochondrial variation and compared their frequencies in 2854
CRC cases and 2822 controls.
MATERIALS AND METHODS
Subjects and samples
A total of 2863 CRC cases (1196 men, 1667 women; mean age at
diagnosis 59.3 years; s.d.±8.7) were ascertained through the
National Study of Colorectal Cancer Genetics (NSCCG). A total
of 2838 healthy individuals were recruited as part of ongoing
National Cancer Research Network genetic epidemiological
studies, NSCCG (1219), the Genetic Lung Cancer Predisposition
Study (GELCAPS) (1999–2004; n¼ 911), and the Royal Marsden
Hospital Trust/Institute of Cancer Research Family History and
DNA Registry (1999– 2004; n¼ 708). These controls (1136 men,
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1702 women; mean age 59.8 years; s.d.±10.8) were the spouses or
unrelated friends of patients with malignancies. None had a
personal history of malignancy at the time of ascertainment. All
cases and controls were British and of European descent, and there
were no obvious differences in the demography of cases and
controls in terms of place of residence within the United Kingdom.
Collection of blood samples and clinico-pathological information
from patients and controls was undertaken with informed consent
and the ethical review board approval in accordance with the
tenets of the Declaration of Helsinki.
Variant selection and genotyping
DNA was extracted from EDTA venous blood samples using
conventional methodologies and quantified using PicoGreen
(Invitrogen, Paisley, UK). We excluded the B0.8 kb of the
hypervariable mtDNA D-loop promoter region/control region
from the study, as variation in this region can only realistically
be addressed by sequencing because of the high mutation rate
associated with this region of the mitochondrial genome. A recent
study identified 144 variants with frequency 41% in Europeans
and defined a set of 64 single nucleotide polymorphisms (SNPs),
which tag all common variants with r240.8 (Saxena et al, 2006).
On the basis of these data and designability scores for the
genotyping platform, we selected 132 tag SNPs, which maximally
capture common mtDNA variation.
Genotyping was conducted using Illumina Infinium Bead
Arrays according to the manufacturer’s protocols. A DNA sample
was deemed to have failed if it generated genotypes at fewer
than 95% of loci. An SNP was deemed to have failed if fewer
than 95% of DNA samples generated a genotype at the locus.
To ensure quality of genotyping, a series of duplicate samples
were genotyped.
The nucleotide positions presented are taken from the
NC_001807 mitochondrial reference sequence in dbSNP. The
mapping between this sequence and the revised Cambridge
reference sequence for each of the 132 variants tested is detailed
in Supplementary Table 1. European mtDNA haplogroups H, I, J,
K, T, U, V, W and X were classified according to the published
references and the Mitomap database (Torroni et al, 1996;
Macaulay et al, 1999; Herrnstadt et al, 2002) (Table 1).
Microsatellite instability in CRCs was determined using the
following methodology: 10 mm sections were cut from formalin-
fixed paraffin-embedded tumours, lightly stained with toluidine
blue, and regions containing at least 60% tumour micro-dissected.
Tumour DNA was extracted using the QIAamp DNA Mini kit
(Qiagen, Crawley, UK) according to the manufacturer’s instruc-
tions and genotyped for the mononucleotide microsatellite loci
BAT25 and BAT26, which are highly sensitive markers of MSI.
Samples showing novel alleles at either BAT26 or BAT25 or both
markers were assigned as MSI (corresponding to a high level of
instability, MSI-H (Boland et al, 1998)).
Statistical and bioinformatic methods
For several of the SNPs, the rare variant was observed in less
than 1% of samples. These variants were excluded from further
analysis. We employed the program Tagger (de Bakker et al, 2005)
to estimate the approximate proportion of common mitochondrial
variation defined by the 144 variants described by Saxena et al
(2006), which was captured by the variants genotyped in our study.
For each individual SNP and haplogroup, comparison of geno-
type frequencies (or presence/absence of haplogroup frequencies)
in cases and controls was initially undertaken using a w2-test with
one degree of freedom and unadjusted odds ratios (ORs) were
calculated. We used logistic regression to calculate ORs adjusted
for age and gender, and their associated 95% confidence intervals.
For each SNP, a one-degree of freedom likelihood ratio test
comparing the model including covariates age and gender with the
model including covariates age, gender and SNP genotype was
performed.
Correction for multiple testing in association studies using a
simple Bonferroni correction may be conservative due to the
assumption of independence between tests. We therefore adopted
an empirical simulation approach based on 10 000 permutations,
thus allowing for correlations between mtDNA variants. At each
iteration case and control labels were permuted at random and the
maximum likelihood ratio test statistic calculated. The significance
level for each SNP was estimated as the proportion of permutation
samples for which this maximum was larger than the observed
value.
We assessed the possibility of interactive effects between each
pair of SNPs that displayed some evidence of association (Po0.1)
by computing the likelihood ratio test statistic for the saturated
model against the main effects model. We also assessed the
possibility that the effect of each SNP on CRC risk was modified by
age by computing the likelihood ratio test statistic for the model
with a genotype-age interaction against the model with genotype
and age terms only.
A number of additional covariates were available for the CRC
cases, including family history of CRC (at least one first-degree
relative with CRC), site of tumour (colon/rectum) and MSI status.
For each SNP and haplogroup, we assessed the association with
CRC risk restricted to case subgroups defined by these covariates.
For each subgroup, logistic regression was used to estimate ORs
adjusted for age and gender and likelihood ratio test statistics were
calculated. All statistical analyses were undertaken in R v.2.4.
RESULTS
Out of the 5701 DNA samples submitted for genotyping, 5676
samples were successfully processed. Genotyping failed in 25
individuals, leaving genotype data for 2854 cases and 2822
controls.
Of the 132 variants for which genotyping were attempted, 125
were satisfactorily genotyped (94.7%), with mean SNP call rates of
Table 1 Classification of haplogroups
Haplogroup G1721A T4217C G4581A T10035C G10399A A12309G T14471C T14767C
H — — — — A — — C
I A — — C G — — —
J — C — — G — — —
K — — — — G G — —
T — C — — A A — —
U — — — — A G — —
V — — A — A — — C
W — — — — A — — —
X A — — — A — C —
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Table 2 Relationship between CRC risk and the sixty-three common mtDNA variants
MAF Adjusted resultsa Unadjusted results
SNP Case Control P-value OR (95% CI) P-value OR (95% CI)
G752A 0.018 0.018 0.99 1.00 (0.68, 1.47) 0.95 0.99 (0.67, 1.46)
G1440A 0.033 0.027 0.18 1.24 (0.91, 1.68) 0.19 1.23 (0.90, 1.67)
G1721A 0.058 0.054 0.54 1.07 (0.86, 1.35) 0.52 1.08 (0.86, 1.35)
T2160C 0.014 0.012 0.61 1.13 (0.71, 1.78) 0.60 1.13 (0.72, 1.79)
G2708A 0.434 0.438 0.75 0.98 (0.88, 1.09) 0.80 0.99 (0.89, 1.10)
G3012A 0.256 0.247 0.41 1.05 (0.93, 1.19) 0.41 1.05 (0.93, 1.19)
T3198C 0.102 0.089 0.10 1.16 (0.97, 1.39) 0.12 1.15 (0.96, 1.38)
A3481G 0.080 0.094 0.09 0.85 (1.02, 0.71) 0.07 0.85 (0.70, 1.02)
A3721G 0.011 0.012 0.55 0.86 (1.40, 0.53) 0.59 0.87 (0.54, 1.42)
G3916A 0.026 0.026 0.88 0.98 (0.70, 1.36) 0.94 0.99 (0.71, 1.37)
C3993T 0.025 0.023 0.65 1.08 (1.53, 0.77) 0.72 1.07 (0.76, 1.50)
A4025G 0.019 0.020 0.75 0.94 (1.37, 0.64) 0.65 0.92 (0.63, 1.34)
T4217C 0.213 0.203 0.32 1.07 (0.94, 1.22) 0.39 1.06 (0.93, 1.20)
T4337C 0.025 0.025 0.99 1.00 (0.72, 1.40) 0.99 1.00 (0.72, 1.40)
T4562C 0.012 0.012 0.99 1.00 (0.62, 1.61) 0.96 0.99 (0.61, 1.59)
G4581A 0.037 0.039 0.64 0.94 (0.71, 1.23) 0.72 0.95 (0.72, 1.25)
G4770A 0.030 0.025 0.20 1.23 (0.90, 1.69) 0.22 1.22 (0.89, 1.67)
A4918G 0.100 0.105 0.58 0.95 (1.13, 0.80) 0.51 0.94 (0.79, 1.12)
T5005C 0.020 0.023 0.60 0.91 (0.63, 1.30) 0.54 0.89 (0.62, 1.28)
A5391G 0.011 0.011 0.80 0.94 (1.54, 0.57) 0.87 0.96 (0.58, 1.57)
G5461A 0.055 0.047 0.21 1.16 (0.92, 1.48) 0.19 1.17 (0.92, 1.48)
T5496C 0.014 0.015 0.67 0.91 (0.59, 1.41) 0.62 0.90 (0.58, 1.39)
A5657G 0.016 0.010 0.06 1.58 (2.56, 0.98) 0.06 1.57 (0.97, 2.52)
C6046T 0.011 0.011 0.80 0.94 (1.54, 0.57) 0.86 0.96 (0.58, 1.57)
T6153C 0.012 0.012 0.90 0.97 (0.60, 1.58) 0.97 0.99 (0.61, 1.61)
T6222C 0.016 0.013 0.27 1.28 (0.82, 1.98) 0.29 1.27 (0.82, 1.97)
G6261A 0.018 0.019 0.83 0.96 (0.65, 1.41) 0.80 0.95 (0.65, 1.40)
C6372T 0.015 0.011 0.22 1.34 (2.12, 0.84) 0.22 1.33 (0.84, 2.11)
G6735A 0.012 0.010 0.45 1.22 (0.73, 2.01) 0.47 1.20 (0.73, 1.99)
A7769G 0.046 0.038 0.11 1.24 (1.61, 0.95) 0.13 1.22 (0.94, 1.58)
G8270A 0.034 0.032 0.61 1.08 (0.81, 1.45) 0.66 1.07 (0.80, 1.43)
G8698A 0.098 0.103 0.61 0.96 (0.80, 1.14) 0.53 0.95 (0.80, 1.12)
A9668G 0.014 0.012 0.48 1.18 (1.86, 0.75) 0.52 1.16 (0.74, 1.83)
T9699C 0.084 0.096 0.12 0.86 (0.72, 1.04) 0.10 0.86 (0.72, 1.03)
T9900C 0.014 0.017 0.41 0.84 (0.55, 1.28) 0.42 0.84 (0.55, 1.28)
T10035C 0.037 0.033 0.37 1.14 (0.86, 1.51) 0.32 1.15 (0.87, 1.53)
A10045G 0.011 0.011 0.79 1.07 (1.78, 0.65) 0.94 1.02 (0.62, 1.69)
T10239C 0.036 0.035 0.99 1.00 (0.76, 1.33) 0.90 1.02 (0.77, 1.35)
G10399A 0.213 0.211 0.87 1.01 (1.15, 0.89) 0.85 1.01 (0.89, 1.15)
T10464C 0.105 0.109 0.69 0.97 (0.82, 1.14) 0.59 0.95 (0.81, 1.13)
A10551G 0.079 0.093 0.08 0.85 (1.02, 0.70) 0.07 0.84 (0.70, 1.01)
G10590A 0.014 0.015 0.62 0.90 (0.58, 1.39) 0.62 0.90 (0.58, 1.38)
T10916C 0.012 0.011 0.82 1.06 (0.65, 1.72) 0.84 1.05 (0.65, 1.71)
G11378A 0.020 0.020 0.87 0.97 (0.67, 1.41) 0.88 0.97 (0.67, 1.41)
A11468G 0.222 0.228 0.66 0.97 (1.10, 0.86) 0.59 0.97 (0.85, 1.09)
T11486C 0.021 0.019 0.61 1.10 (0.76, 1.60) 0.61 1.10 (0.76, 1.60)
A11813G 0.082 0.084 0.90 0.99 (1.19, 0.82) 0.79 0.97 (0.81, 1.18)
G11915A 0.018 0.021 0.56 0.89 (0.61, 1.31) 0.52 0.88 (0.61, 1.29)
A12309G 0.223 0.229 0.70 0.98 (1.11, 0.86) 0.64 0.97 (0.86, 1.10)
G12373A 0.224 0.229 0.69 0.97 (0.86, 1.10) 0.62 0.97 (0.86, 1.10)
T12415C 0.019 0.020 0.72 0.93 (0.64, 1.36) 0.80 0.95 (0.66, 1.39)
T12706C 0.074 0.072 0.91 0.99 (0.81, 1.21) 0.81 1.02 (0.84, 1.25)
A13781G 0.035 0.034 0.93 1.01 (1.35, 0.76) 0.83 1.03 (0.77, 1.37)
A14234G 0.082 0.085 0.83 0.98 (1.18, 0.81) 0.72 0.97 (0.80, 1.17)
T14471C 0.019 0.013 0.09 1.43 (0.94, 2.17) 0.08 1.44 (0.95, 2.18)
T14767C 0.492 0.498 0.57 0.97 (0.87, 1.08) 0.64 0.98 (0.88, 1.08)
T14799C 0.162 0.164 0.94 0.99 (0.86, 1.15) 0.85 0.99 (0.86, 1.14)
G15044A 0.042 0.045 0.57 0.93 (0.72, 1.20) 0.63 0.94 (0.73, 1.21)
A15219G 0.041 0.041 0.99 1.00 (1.30, 0.77) 0.98 1.00 (0.77, 1.30)
C15834T 0.021 0.021 0.99 1.00 (1.44, 0.70) 0.98 1.01 (0.70, 1.45)
C15905T 0.037 0.039 0.57 0.92 (1.22, 0.70) 0.66 0.94 (0.72, 1.24)
A15925G 0.061 0.062 0.80 0.97 (1.21, 0.78) 0.90 0.99 (0.79, 1.23)
G15929A 0.100 0.104 0.64 0.96 (0.81, 1.14) 0.56 0.95 (0.80, 1.13)
CI¼ confidence interval; MAF¼minor allele frequency; OR¼ odds ratio. aAdjusted for age and gender.
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99.9 and 99.8% in cases and controls, respectively. Of these 125
SNPs, eight were monomorphic and an additional 54 had the
minor variant observed in less than 1% of samples and were
excluded from further analysis, leaving 63 polymorphic variants.
Only one SNP (A15925G) was triallelic in samples analysed with
one heterozygote observed among cases. This genotype was treated
as missing for the analysis. Genotypes from duplicate samples
displayed 100% concordance.
One variant (G10590A), polymorphic in our samples was not
observed by (Saxena et al, 2006), and nine variants observed to be
polymorphic in their study were either monomorphic or had very
low frequency in our samples (Supplementary Table 2). Given
these caveats, our data indicated that 79.3% of polymorphic
variants were captured with r240.8, whereas 92.2% of variants
with MAF45% were captured with r240.8.
Four SNPs showed nominal levels of association with CRC
risk (Po0.1; Table 2). The most strongly associated was A5657G,
with a P-value of 0.06; non-significant after adjustment for
multiple testing by permutation. All nine common European
haplogroups (H, I, J, K, T, U, V, W and X) were observed in both
cases and controls. Haplogroup J was slightly over-represented in
cases, whereas haplogroup K was slightly under-represented,
although these observations were statistically non-significant
(Table 3). Adjustment for age and gender did not impact on the
findings.
Interactions between the four SNPs that showed an association
with CRC risk at the 10% level of significance were examined by
fitting full logistic regression models for each pair, generating six
models, and comparing with the main effects model for each pair.
Owing to small MAFs, it was only possible to evaluate the interaction
for three of the pairs. For each of these there was no significant
evidence of interactive effects. Furthermore, there was no evidence of
any differential effect of genotype by either age or gender.
For all 2854 genotyped cases, information was available on site
of CRC (1743 colonic, 1111 rectal tumours) and family history (398
individuals with at least one first-degree relative affected by CRC,
2456 with no recorded family history), and 1222 of the cases had
been evaluated for MSI status (151 MSI, 1071 MSS cases).
Subgroup analysis by site indicated stronger evidence of associa-
tion between mtDNA variants and colon cancer, with five variants
showing significant association (Po0.05) whereas there was no
evidence for an association between any variant and rectal cancer
(P40.1 for all variants). The variant A5657G was most strongly
associated with the risk of colonic tumour (P¼ 0.02), albeit non-
significant after adjustment for multiple testing. Stratification by
MSI status showed that three variants were associated with risk of
CRC for MSI cases, with the strongest association for T4562C
(P¼ 4.6 103), non-significant after adjustment for multiple
testing. There was no evidence for association between any SNP
and CRC in MSS cases (P40.05 for all variants). Stratification by
family history status did not alter the overall findings.
DISCUSSION
It is entirely plausible that genetic variation in mitochondrial
genome might influence cancer risk given the increasing evidence
implicating hypoxia in the development of cancer and the pivotal
role of mitochondrial function in cellular energy metabolism.
Previous studies have tested small numbers of mtDNA variants
for an association with a variety of traits, typically focusing on the
nine canonical haplogroups, with limited tagging coverage
generally capturing o40% of common variation (r240.8). To
generate a more comprehensive analysis of the relationship
between mitochondrial variation and CRC risk we have analysed
variants that capture 79% of all polymorphic variants (MAF41%)
and 92% of variants with MAF45% (r240.8). A further strength
of our study is that our analysis has been based on a large case–
control series. We genotyped 132 mtDNA variants and analysed
data from the 63 variants with frequencies 41%. Under the
assumption that the 63 tests were independent, our study therefore
had 70% power to detect a variant with a frequency of 5%
conferring a 1.5-fold increase in risk of CRC. Moreover, for
variants with MAFs of 10% or greater, our study had 480% power
to identify variants conferring a 1.3-fold increase in risk.
Despite our study being a well-powered evaluation capturing the
majority of common variation in mtDNA, our findings do not
support the hypothesis that common mtDNA variants play a
significant role in inherited CRC. Specifically, results from our
association tests of all common mtDNA variants and the risk of
CRC show that there is no single common coding-region mtDNA
variant or haplogroup that strongly influences risk of developing
CRC. It is however, entirely possible that any genetic variation in
mitochondria influencing CRC risk may be in the form of low
frequency variants, although we have no evidence from our data
that this is the case. Alternatively the impact of variants may be
restricted to a subset of CRC, as there are differences in the
biological basis of CRC according to site.
Observations based on post hoc analyses are inherently prone to
generating spurious associations. Accepting such caveats it is,
however, noteworthy that we found a stronger relationship
between A5657G and colonic rather than rectal disease. There
was also evidence for an association between risk of MSI CRC and
T4562C. Tumour hypoxia has been reported to cause a functional
loss of DNA mismatch repair system as a result of downregulation
of MMR genes, principally involving MLH1 (Mihaylova et al, 2003;
Bindra et al, 2007; Nakamura et al, 2008) thereby in keeping with
the observation. Although attractive, such a postulate requires
Table 3 Risk of CRC associated with the nine common European haplogroups
Frequency (%) Adjusted resultsa Unadjusted results
Haplogroup Case Control P-value OR (95% CI) P-value OR (95% CI)
H 1258 (44.1) 1261 (44.7) 0.59 0.99 (0.94–1.04) 0.65 0.99 (0.94–1.04)
I 98 (3.4) 88 (3.1) 0.57 1.04 (0.90–1.21) 0.50 1.05 (0.91–1.22)
J 300 (10.5) 263 (9.3) 0.12 1.07 (0.98–1.17) 0.13 1.07 (0.98–1.17)
K 184 (6.4) 213 (7.5) 0.10 0.92 (0.83–1.02) 0.10 0.92 (0.83–1.02)
T 303 (10.6) 306 (10.8) 0.91 1.00 (0.91–1.08) 0.78 0.99 (0.91–1.07)
U 452 (15.8) 430 (15.2) 0.47 1.03 (0.96–1.10) 0.53 1.02 (0.95–1.10)
V 104 (3.6) 108 (3.8) 0.64 0.97 (0.84–1.11) 0.72 0.97 (0.85–1.12)
W 67 (2.3) 76 (2.7) 0.33 0.92 (0.78–1.09) 0.41 0.93 (0.79–1.10)
X 42 (1.5) 31 (1.1) 0.21 1.16 (0.92–1.47) 0.21 1.16 (0.92–1.46)
Undefined 46 (1.6) 46 (1.6) 1.00 1.00 (0.81–1.23) 0.96 0.99 (0.81–1.22)
CI¼ confidence interval; OR¼ odds ratio. aAdjusted for age and gender.
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validation in additional independent datasets. As A5657G is non-
coding and T4562C is a synonymous change, any effect is likely to
be indirect, which is possibly mediated through an untyped SNP.
A limitation of our study is that it does not address the role of
mtDNA heteroplasmy in CRC. Typically, blood DNA exhibits
much less heteroplasmy than non-dividing tissues. Indeed in the
5676 DNA samples genotyped, only one heterozygote call was
observed although it is possible that this is because of analytical
limitations of the platform employed. However, as the known rare
mitochondrial diseases exhibit pronounced heteroplasmy, it is
unlikely that mtDNA heteroplasmy for such variants will have
significantly influenced our findings.
In conclusion, our results provide no support that common
mtDNA variation plays a role in inherited predisposition to CRC. It
is however, possible that mitochondria may be involved in gene–
gene and gene–environment interactions that may affect disease
risk. To address such hypotheses requires studies based on very
large sample sizes that incorporate data on non-genetic covariates.
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